Take Surge Pricing to the Limit. Then Go Further. The New York Times
The New York Times’ John Schwartz asks Eric Dezenhall about why Martin Shkreli the Turing Pharmaceutical executive who raised its drug Daraprim price to $750 a pill from $13.50 was vilified so quickly. Read the article for Eric’s simple answer.
